By BullScreen Editorial Team 
Gland Pharma shares surged nearly 12% on Tuesday, August 11, hitting a fresh 52-week high of ₹2,987 apiece after the company reported a strong first quarter of FY27. Investors responded positively to higher profits, robust US sales and improved growth guidance.
The stock opened at ₹2,667.30 in the previous session and touched ₹2,987 during early trade. It was trading near ₹2,977 during the session.
Gland Pharma’s consolidated net profit rose 47% year-on-year to ₹317 crore in Q1 FY27, compared with ₹215 crore a year earlier. Revenue from operations increased 19.5% to ₹1,800 crore from ₹1,506 crore.
The US business remained the key growth driver, with revenue rising 32% YoY to ₹981 crore. Europe revenue also increased about 20% to ₹395 crore. EBITDA climbed 33% to ₹489 crore, while the EBITDA margin improved to 27.16% from 24.44%.
The company’s CDMO business contributed 50% of total revenue and grew 20% YoY. A recently signed CDMO partnership has an estimated annualised revenue potential of $90–100 million once all products are commercialised.
For investors tracking Q1 results 2027, management’s upgraded 15% constant-currency growth guidance, from 12–13% earlier, is a key positive.
Jefferies said several challenges appear to be easing, citing Cenexi breakeven, new contracts and expansion into complex products. Goldman Sachs, however, flagged potential margin pressure and delays in Cenexi improvement. Approval of the RTU bag line in Q3 could provide further upside.